Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications

Liver International

Volumn 36, Issue 2, 2016, Pages 158-165

  Dara, Lily ^a   Liu, Zhang Xu ^a   Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Drug induced liver injury; Hepatotoxicity; Human leukocyte antigen; Immune tolerance; T cells

Indexed keywords

INTERLEUKIN 10; IPILIMUMAB; LUMIRACOXIB; NIVOLUMAB; PEMBROLIZUMAB; PROSTAGLANDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; HLA ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DISEASE COURSE; DRUG SENSITIVITY; EOSINOPHIL COUNT; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HUMAN; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; ADAPTATION; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADAPTATION, PHYSIOLOGICAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; SEVERITY OF ILLNESS INDEX;

EID: 84955684315     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12988     Document Type: Article

References (58)

1. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
2. Williams GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002; 30: 41-53.
3. Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 1967; 215: 744-5.
4. Callery MP, Kamei T, Flye MW. The effect of portacaval shunt on delayed-hypersensitivity responses following antigen feeding. J Surg Res 1989; 46: 391-4.
5. Yang R, Liu Q, Grosfeld JL, Pescovitz MD. Intestinal venous drainage through the liver is a prerequisite for oral tolerance induction. J Pediatr Surg 1994; 29: 1145-8.
6. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472-6.
7. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol 2015; 62(1 Suppl): S170-85.
8. Lohse AW, Knolle PA, Bilo K, et al. Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells and Kupffer cells. Gastroenterology 1996; 110: 1175-81.
9. Sorensen KK, Mccourt P, Berg T, et al. The scavenger endothelial cell: a new player in homeostasis and immunity. Am J Physiol Regul Integr Comp Physiol 2012; 303: R1217-30.
10. Knolle PA, Uhrig A, Protzer U, et al. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells. Hepatology 1998; 27: 93-9.
11. Knolle PA, Schmitt E, Jin S, et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology 1999; 116: 1428-40.
12. Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447-55.
13. Knolle P, Schlaak J, Uhrig A, et al. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995; 22: 226-9.
14. Dieter P, Schulze-Specking A, Karck U, Decker K. Prostaglandin release but not superoxide production by rat Kupffer cells stimulated in vitro depends on Na+/H+ exchange. Eur J Biochem 1987; 170: 201-6.
15. Rieder H, Ramadori G, Allmann KH, Meyer Zum Buschenfelde KH. Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells. J Hepatol 1990; 11: 359-66.
16. Knolle PA, Germann T, Treichel U, et al. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol 1999; 162: 1401-7.
17. Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-7.
18. Erhardt A, Biburger M, Papadopoulos T, Tiegs G. IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology 2007; 45: 475-85.
19. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 2009; 50: 612-21.
20. Dunham RM, Thapa M, Velazquez VM, et al. Hepatic stellate cells preferentially induce Foxp3 + regulatory T cells by production of retinoic acid. J Immunol 2013; 190: 2009-16.
21. Yang HR, Chou HS, Gu X, et al. Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling. Hepatology 2009; 50: 1981-91.
22. Schildberg FA, Wojtalla A, Siegmund SV, et al. Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism. Hepatology 2011; 54: 262-72.
23. Kiyono H, Mcghee JR, Wannemuehler MJ, Michalek SM. Lack of oral tolerance in C3H/HeJ mice. J Exp Med 1982; 155: 605-10.
24. Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity 1994; 1: 741-9.
25. Gorczynski RM. Adoptive transfer of unresponsiveness to allogeneic skin grafts with hepatic gamma delta + T cells. Immunology 1994; 81: 27-35.
26. Gorczynski RM, Chen Z, Hoang Y, Rossi-Bergman B. A subset of gamma delta T-cell receptor-positive cells produce T-helper type-2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization. Immunology 1996; 87: 381-9.
27. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol 2014; 14: 286-92.
28. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388-96.
29. Kaplowitz N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 2013; 58: 15-7.
30. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.
31. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015; 148: 1340-52 e7.
32. Tsutsui H, Terano Y, Sakagami C, et al. Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992; 149: 706-16.
33. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57: 727-39.
34. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68: 181-90.
35. Senior J. Hepatic side effects. In: Urbán L., Patel VF., Vaz RJ., eds. Antitargets and Dryg safetty, 1st edn. Wiley-VCH Verlag GmbH & Co. KGaA, 2015: 81-106.
36. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.
37. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 1-5.
38. Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015; 35: 1801-8.
39. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-4.
40. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-26.
41. Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015; 61: 1332-42.
42. Chakraborty M, Fullerton AM, Semple K, et al. Drug-induced allergic hepatitis developed in mice when myeloid-derived suppressor cells were depleted prior to halothane treatment. Hepatology 2015; 62: 546-57.
43. Mak A, Uetrecht J. The role of CD8 T cells in amodiaquine-induced liver injury in PD1-/- mice cotreated with anti-CTLA-4. Chem Res Toxicol 2015; 28: 1567-73.
44. Uetrecht J, Kaplowitz N. Inhibition of immune tolerance unmasks drug-induced allergic hepatitis. Hepatology 2015; 62: 346-8.
45. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009; 106: 14728-33.
46. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430-40.
47. Pachkoria K, Lucena MI, Crespo E, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 2008; 49: 107-14.
48. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-24.
49. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995; 27: 537-41.
50. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
51. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.
52. Cheng R, Cooper A, Kench J, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 2015; 30: 657-66.
53. Ahmed T, Pandey R, Shah B, Black J. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep 2015; 2015. pii: bcr2014208102 doi:10.1136/bcr-2014-208102.
54. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31: 1071-7.
55. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-40.
56. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35: 76-83.
57. Iwanaga N, Origuchi T, Terada K, et al. Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept. Mod Rheumatol 2014; 24: 874-6.
58. Hoofnagle J. LiverTox. 2015 Available at http://livertox.nih.gov/Abatacept.htm. Accessed 20 August 2015.